• To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)
• 90 day trial, with botox being injected at baseline/screening visit. Photos will be taken throughout the study and patients will be evaluated by masked injector evaluator and a masked evaluator. Patient will complete a subject evaluation at each visit. Follow-up visits occur at Day 3, 7, 14, 30 and 90.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
5
1.5-3 units of Botox/lesion
.1 cc bacteriostatic saline/lesion
DeNova Research
Chicago, Illinois, United States
Change in Mean Lesion Count From Baseline at 90 Days
To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)
Time frame: Baseline and 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.